Prof. Dr. Christian Burholt LL.M.

Advised the international pharmaceutical laboratory Servier on the acquisition of the Agios Pharmaceuticals oncology business.

Advised the French supplier of industrial gases group Air Liquide on the planned sale of the Schülke Group to the Swedish financial investor EQT.

Advised EP Power Europe, a.s. (EPPE), a subsidiary of Czech energy supply company Energetický a průmyslový holding, a.s. (EPH) in connection with the acquisition of STEAG Power Minerals Group. 

Advised global pharmaceutical company Lundbeck on the acquisition of Alder BioPharmaceuticals, a company committed to migraine treatment and prevention.

Advised ALBA Group in relation to an investment of the Techcent-owning family Deng in the ALBA Group.

Advised German hospital owners on various acquisitions in the hospital sector.

Advised an international pharmaceutical company on the out-licensing of a medicinal product to a major international pharmaceutical company (transaction was used as a precedent by the German Federal Cartel Office with regard to the requirements of the new value-based transaction threshold).

Advised CureVac AG on a strategic collaboration agreement with GlaxoSmithKline (GSK) for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens.

Advised international pharmaceutical and medical device companies on various antitrust matters, including the implementation of price and rebate schemes, supply quota systems, direct-to-pharmacy distribution, actions against statutory health insurance funds (associations) due to joint tendering procedures etc.

Advised a major international company on the development and implementation of a new compliance system in the area of antitrust in Germany and the EU.